Whitfield Represents THL Partners on Majority Investment in Celerion
Overview
THL Partners agreed to take a majority position in Celerion, a clinical pharmacology and bioanalytical services business, according to the source announcement.
Operating purpose
The investment was intended to expand clinical and laboratory capabilities serving pharmaceutical and biotechnology companies developing new therapies.
Transaction timing
Completion was expected in 2026, subject to customary conditions. The published statement describes the investment agreement, not a confirmed subsequent closing.
Advisory coverage
The source names Chris Elder and Jeremy Mandell among corporate advisers, alongside healthcare, finance, tax, technology, employment, environmental and competition specialists supporting the transaction.
